Key result
COVID-19 mRNA vaccination linked to acute, rapidly reversible myocarditis after second dose.
Why the study?
Post-vaccination myocarditis has emerged as a rare side effect of COVID-19 vaccination, but its pathogenesis remains unclear and warrants further investigation.
Does COVID-19 vaccination trigger acute myocarditis in healthy young adults?
Case Report (n=1)
No
Does COVID-19 vaccination trigger acute myocarditis in healthy young adults?
This case report highlights that mRNA COVID-19 vaccination can be a potential, albeit rare, trigger for acute myocarditis that may present with a mild and reversible clinical course.
Answers are grounded in this paper and cite their sources.
Single case of mild reversible myocarditis post-mRNA vaccine; hypothesis-generating and should not change practice or recommendations.
Recently, new vaccine platforms-including mRNA vaccines for coronavirus disease 2019 (COVID-19) have been given emergency use authorization in Japan. Here, we present a rare case of myocarditis following a COVID-19 vaccine. In this case, myocarditis was confirmed by cardiac magnetic resonance imaging, endomyocardial biopsy, and troponin levels. The degree of myocardial inflammation in the endomyocardial biopsy samples was mild and the patient's clinical course was not severe. Although the pathology of myocarditis in this case was mild, further investigation would be needed.<Learning objective: Vaccination for coronavirus disease 2019 is advancing worldwide, but post-vaccination myocarditis is getting attention as a rare side effect. Although the myocarditis in this case was mild, the pathogenesis of the disease is unclear and needs to be thoroughly investigated in the vaccination.>
No takes yet. Share an insight, caveat, or question.
Nagasaka et al. (2021) conducted a case report in Acute myocarditis associated with COVID-19 vaccination (n=1). COVID-19 mRNA vaccine (Pfizer-BioNTech BNT16B2b2) was evaluated on Diagnosis and clinical course of acute myocarditis. Acute myocarditis developed in a 23-year-old man 3 days after his second dose of a COVID-19 mRNA vaccine, presenting with a mild and rapidly reversible clinical course.
Synapse has enriched 10 related papers. Consider them for comparative context: